The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines

William A. Robinson, Troy L. Miller, Elizabeth A. Harrold, Lynne T. Bemis, Benjamin M.R. Brady, R. Peter Nelson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. Flavopiridol has been shown to mimic, in part, the effect of the cell cycle control gene p16, which is frequently lost or mutated in malignant melanoma, making it an ideal candidate for targeted therapy in this disease. In these studies we investigated the effect of flavopiridol, at various concentrations, on the growth and gene expression of nine human melanoma cell lines with intact, absent or mutated p16. A cytostatic effect of flavopiridol on the growth of six melanoma cell lines with a mutated or non-expressed p16 (p16-) was seen at low concentrations of flavopiridol (mean 50% inhibitory concentration [IC50] = 12.5 nM), while the three melanoma cell lines with intact p16 (p16+) required higher concentrations (mean IC50 = 25 nM) to produce this effect. Apoptotic cell death increased with increasing concentrations of flavopiridol in both p16- and p16+ cells. Exposure of cells to high flavopiridol concentrations (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. No change in BCL2 expression was found after exposure to IC50 concentrations of flavopiridol. These data indicate that flavopiridol in low, clinically achievable concentrations may have significant cytostatic effects, particularly in p16- melanoma cells, and may provide new molecular-based therapies for melanoma, particularly when combined with agents that target anti-apoptotic mechanisms.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalMelanoma Research
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2003

Fingerprint

alvocidib
Melanoma
Cell Line
Growth
Inhibitory Concentration 50
Cytostatic Agents
Cell Cycle Checkpoints
Gene Expression
cdc Genes
Cyclin-Dependent Kinases

Keywords

  • Flavopiridol
  • Melanoma
  • P16

Cite this

Robinson, W. A., Miller, T. L., Harrold, E. A., Bemis, L. T., Brady, B. M. R., & Nelson, R. P. (2003). The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma Research, 13(3), 231-238. https://doi.org/10.1097/00008390-200306000-00002

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. / Robinson, William A.; Miller, Troy L.; Harrold, Elizabeth A.; Bemis, Lynne T.; Brady, Benjamin M.R.; Nelson, R. Peter.

In: Melanoma Research, Vol. 13, No. 3, 01.06.2003, p. 231-238.

Research output: Contribution to journalArticle

Robinson, WA, Miller, TL, Harrold, EA, Bemis, LT, Brady, BMR & Nelson, RP 2003, 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines', Melanoma Research, vol. 13, no. 3, pp. 231-238. https://doi.org/10.1097/00008390-200306000-00002
Robinson, William A. ; Miller, Troy L. ; Harrold, Elizabeth A. ; Bemis, Lynne T. ; Brady, Benjamin M.R. ; Nelson, R. Peter. / The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. In: Melanoma Research. 2003 ; Vol. 13, No. 3. pp. 231-238.
@article{814b05294aeb430aa282101166cb6312,
title = "The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines",
abstract = "Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. Flavopiridol has been shown to mimic, in part, the effect of the cell cycle control gene p16, which is frequently lost or mutated in malignant melanoma, making it an ideal candidate for targeted therapy in this disease. In these studies we investigated the effect of flavopiridol, at various concentrations, on the growth and gene expression of nine human melanoma cell lines with intact, absent or mutated p16. A cytostatic effect of flavopiridol on the growth of six melanoma cell lines with a mutated or non-expressed p16 (p16-) was seen at low concentrations of flavopiridol (mean 50{\%} inhibitory concentration [IC50] = 12.5 nM), while the three melanoma cell lines with intact p16 (p16+) required higher concentrations (mean IC50 = 25 nM) to produce this effect. Apoptotic cell death increased with increasing concentrations of flavopiridol in both p16- and p16+ cells. Exposure of cells to high flavopiridol concentrations (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. No change in BCL2 expression was found after exposure to IC50 concentrations of flavopiridol. These data indicate that flavopiridol in low, clinically achievable concentrations may have significant cytostatic effects, particularly in p16- melanoma cells, and may provide new molecular-based therapies for melanoma, particularly when combined with agents that target anti-apoptotic mechanisms.",
keywords = "Flavopiridol, Melanoma, P16",
author = "Robinson, {William A.} and Miller, {Troy L.} and Harrold, {Elizabeth A.} and Bemis, {Lynne T.} and Brady, {Benjamin M.R.} and Nelson, {R. Peter}",
year = "2003",
month = "6",
day = "1",
doi = "10.1097/00008390-200306000-00002",
language = "English (US)",
volume = "13",
pages = "231--238",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines

AU - Robinson, William A.

AU - Miller, Troy L.

AU - Harrold, Elizabeth A.

AU - Bemis, Lynne T.

AU - Brady, Benjamin M.R.

AU - Nelson, R. Peter

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. Flavopiridol has been shown to mimic, in part, the effect of the cell cycle control gene p16, which is frequently lost or mutated in malignant melanoma, making it an ideal candidate for targeted therapy in this disease. In these studies we investigated the effect of flavopiridol, at various concentrations, on the growth and gene expression of nine human melanoma cell lines with intact, absent or mutated p16. A cytostatic effect of flavopiridol on the growth of six melanoma cell lines with a mutated or non-expressed p16 (p16-) was seen at low concentrations of flavopiridol (mean 50% inhibitory concentration [IC50] = 12.5 nM), while the three melanoma cell lines with intact p16 (p16+) required higher concentrations (mean IC50 = 25 nM) to produce this effect. Apoptotic cell death increased with increasing concentrations of flavopiridol in both p16- and p16+ cells. Exposure of cells to high flavopiridol concentrations (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. No change in BCL2 expression was found after exposure to IC50 concentrations of flavopiridol. These data indicate that flavopiridol in low, clinically achievable concentrations may have significant cytostatic effects, particularly in p16- melanoma cells, and may provide new molecular-based therapies for melanoma, particularly when combined with agents that target anti-apoptotic mechanisms.

AB - Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. Flavopiridol has been shown to mimic, in part, the effect of the cell cycle control gene p16, which is frequently lost or mutated in malignant melanoma, making it an ideal candidate for targeted therapy in this disease. In these studies we investigated the effect of flavopiridol, at various concentrations, on the growth and gene expression of nine human melanoma cell lines with intact, absent or mutated p16. A cytostatic effect of flavopiridol on the growth of six melanoma cell lines with a mutated or non-expressed p16 (p16-) was seen at low concentrations of flavopiridol (mean 50% inhibitory concentration [IC50] = 12.5 nM), while the three melanoma cell lines with intact p16 (p16+) required higher concentrations (mean IC50 = 25 nM) to produce this effect. Apoptotic cell death increased with increasing concentrations of flavopiridol in both p16- and p16+ cells. Exposure of cells to high flavopiridol concentrations (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. No change in BCL2 expression was found after exposure to IC50 concentrations of flavopiridol. These data indicate that flavopiridol in low, clinically achievable concentrations may have significant cytostatic effects, particularly in p16- melanoma cells, and may provide new molecular-based therapies for melanoma, particularly when combined with agents that target anti-apoptotic mechanisms.

KW - Flavopiridol

KW - Melanoma

KW - P16

UR - http://www.scopus.com/inward/record.url?scp=0037840371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037840371&partnerID=8YFLogxK

U2 - 10.1097/00008390-200306000-00002

DO - 10.1097/00008390-200306000-00002

M3 - Article

C2 - 12777976

AN - SCOPUS:0037840371

VL - 13

SP - 231

EP - 238

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -